Publications by authors named "Lonnie Brent"
Article Synopsis
- - Infusion-related reactions (IRRs) are common with therapies like chemotherapy and immunotherapy, and diphenhydramine has been the primary IV antihistamine used for over 60 years despite lacking FDA approval for this purpose.
- - In 2019, IV cetirizine was approved and offered a safer alternative with fewer side effects compared to diphenhydramine, proving equally effective in managing IRRs while potentially reducing treatment time and visits.
- - The FDA has required many infusion products to include premedication guidelines, suggesting that IV cetirizine should be actively considered for preventing and managing IRRs in clinical settings.
Pretreatment with antihistamines for the prevention of hypersensitivity infusion reactions is recommended for certain biologics and chemotherapies. Cetirizine is the first injectable second-generation antihistamine recently approved for acute urticaria. A randomized, exploratory phase 2 study evaluated intravenous (IV) cetirizine 10 mg versus IV diphenhydramine 50 mg as pretreatment in patients receiving an anti-CD20 agent or paclitaxel.
View Article and Find Full Text PDFRecent advances have highlighted the importance of long-term, continuous treatment in multiple myeloma (MM) to improve survival. However, treatment burden continues to negatively impact the real-world duration of MM therapy, and strategies to limit the adverse impact of treatment on patient quality of life are therefore particularly important. Oral MM therapies include the immunomodulatory drugs lenalidomide, thalidomide, and pomalidomide; the alkylating agents melphalan and cyclophosphamide; the histone deacetylase inhibitor panobinostat; the corticosteroids prednisone and dexamethasone; and the proteasome inhibitor ixazomib.
View Article and Find Full Text PDF